---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-01-18T20:17:59.037646'
end_time: '2026-01-18T20:24:56.777649'
duration_seconds: 417.74
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: BAG1
  gene_symbol: BAG1
  uniprot_accession: Q99933
  protein_description: 'RecName: Full=BAG family molecular chaperone regulator 1;
    Short=BAG-1; AltName: Full=Bcl-2-associated athanogene 1;'
  gene_info: Name=BAG1; Synonyms=HAP;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: BAG_chaperone_regulator. (IPR039773); BAG_dom_sf. (IPR036533);
    BAG_domain. (IPR003103); Ubiquitin-like_dom. (IPR000626); Ubiquitin-like_domsf.
    (IPR029071)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 23
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q99933
- **Protein Description:** RecName: Full=BAG family molecular chaperone regulator 1; Short=BAG-1; AltName: Full=Bcl-2-associated athanogene 1;
- **Gene Information:** Name=BAG1; Synonyms=HAP;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** BAG_chaperone_regulator. (IPR039773); BAG_dom_sf. (IPR036533); BAG_domain. (IPR003103); Ubiquitin-like_dom. (IPR000626); Ubiquitin-like_domsf. (IPR029071)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "BAG1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'BAG1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **BAG1** (gene ID: BAG1, UniProt: Q99933) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q99933
- **Protein Description:** RecName: Full=BAG family molecular chaperone regulator 1; Short=BAG-1; AltName: Full=Bcl-2-associated athanogene 1;
- **Gene Information:** Name=BAG1; Synonyms=HAP;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** BAG_chaperone_regulator. (IPR039773); BAG_dom_sf. (IPR036533); BAG_domain. (IPR003103); Ubiquitin-like_dom. (IPR000626); Ubiquitin-like_domsf. (IPR029071)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "BAG1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'BAG1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **BAG1** (gene ID: BAG1, UniProt: Q99933) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan and verification
- Identity check: The target is human BAG1 (UniProt Q99933), also known as Bcl‑2‑associated athanogene‑1 (BAG‑1). Contemporary reviews and primary work describe BAG‑1 as a human Hsp70/Hsc70 co‑chaperone with a C‑terminal BAG domain and an N‑terminal ubiquitin‑like (UBL) region, consistent with the UniProt domain list. Prior literature names for BAG‑1 (e.g., RAP46) are also used in human studies; no conflicting non‑human or alternative gene symbol usage is used here. (lin2025onebagdoesntc pages 11-12, maestrolopez2025structuresofthe pages 1-4)

Executive summary
BAG‑1 is a human Hsp70/Hsc70 co‑chaperone and nucleotide exchange factor (NEF) that accelerates ADP release from Hsp70 via its conserved C‑terminal BAG domain. Its N‑terminal UBL domain binds the 26S proteasome (Rpn1), coupling Hsp70‑bound substrates to proteasomal degradation. Alternative translation initiation produces isoforms with distinct localization: BAG‑1L (nuclear, with NLS) modulates steroid receptors (ER/AR), whereas BAG‑1M and BAG‑1S are predominantly cytosolic. BAG‑1 interfaces with apoptotic and signaling proteins including BCL2 and RAF1, and it participates in proteostasis triage, generally biasing toward UPS degradation, in contrast to BAG3 which favors autophagy; the balance between BAG‑1 and BAG‑3 affects client fate. Recent advances (2024–2025) resolved a ternary Hsp70–BAG1–proteasome complex by cryo‑EM/XL‑MS and explored small‑molecule BAG‑1 modulators (e.g., Thio‑2) in castration‑resistant prostate cancer (CRPC). Clinically, newer pan‑cancer bioinformatics and liposarcoma cohorts associated higher BAG1 with more favorable outcomes, aligning with earlier breast cancer meta‑analyses showing improved survival with high BAG‑1 expression. (maestrolopez2025structuresofthe pages 4-7, maestrolopez2025structuresofthe pages 1-4, neeb2024thio2inhibitskey pages 1-2, lian2024decipheringtheprognostic pages 3-5, lian2024decipheringtheprognostic pages 12-13, papadakis2017bag1asa pages 7-8)

1) Key concepts and definitions
- Molecular identity and domains
  - BAG‑1 is a co‑chaperone/NEF for Hsp70/Hsc70 mediated by its C‑terminal BAG domain. Structural and biochemical studies confirm that BAG‑1’s BAG domain binds the Hsp70 nucleotide‑binding domain (NBD) to promote nucleotide exchange. (maestrolopez2025structuresofthe pages 1-4)
  - BAG‑1 contains an N‑terminal ubiquitin‑like (UBL) domain that binds the 26S proteasome subunit Rpn1, enabling direct coupling of Hsp70‑bound clients to the proteasome. Recent structural work places BAG‑1’s UBL at the Rpn1 T2 site. (maestrolopez2025structuresofthe pages 4-7, maestrolopez2025structuresofthe pages 1-4)
- Isoforms and basic localization logic
  - Alternative translation start sites produce multiple BAG‑1 isoforms; widely used nomenclature recognizes BAG‑1L (≈p50), BAG‑1M (≈p46), and BAG‑1S (≈p36). BAG‑1L contains an N‑terminal nuclear localization sequence and is predominantly nuclear; BAG‑1M/S are mainly cytosolic. (neeb2024thio2inhibitskey pages 1-2, lin2025onebagdoesnt pages 3-4)
- Primary biochemical role
  - As an Hsp70/Hsc70 NEF, BAG‑1 accelerates ADP release to reset Hsp70 for another substrate cycle; via its UBL, BAG‑1 functionally links Hsp70 clients to the proteasome, promoting proteostasis through the UPS. (maestrolopez2025structuresofthe pages 1-4, maestrolopez2025structuresofthe pages 4-7)
- Interaction network and pathway placement
  - BAG‑1 binds BCL2 and interacts with RAF1; BAG‑1L modulates steroid receptor activity (ER/AR). Within proteostasis, BAG‑1 tends to bias client triage to the UPS, whereas BAG3 promotes autophagy; family‑level context highlights a BAG1:BAG3 balance in determining fate. (lin2025onebagdoesntc pages 11-12, lin2025onebagdoesnt pages 3-4)

2) Recent developments and latest research (prioritizing 2023–2024)
- Structural and mechanistic advances in proteasome coupling (2025 preprint; mechanistic relevance in 2023–2024 context)
  - Cryo‑EM and XL‑MS reveal a ternary Hsp70–BAG1–Rpn1 complex, with quantitative affinities (KD ≈ 50 nM for Hsp70NBD; ≈ 500 nM for Rpn1). UBL occupancy at Rpn1 T2 is visualized. BAG‑1 binding remodels proteasome regulatory particle conformations, distorting the AAA+ ATPase spiral and creating a cavity above the 20S CP gate, supporting a ubiquitin‑independent substrate‑transfer mechanism from Hsp70 to the proteasome. URL: https://doi.org/10.1101/2025.01.22.633148 (posted 2025‑01‑22). (maestrolopez2025structuresofthe pages 4-7, maestrolopez2025structuresofthe pages 1-4)
- Small‑molecule modulation of BAG‑1 in CRPC (2024)
  - In CRPC models, BAG‑1L’s BAG domain participates in AR N‑terminal domain interaction and transactivation. Thio‑2 and other compounds suppress AR signaling and growth of resistant models. Notably, the Thio‑2 phenotype was not fully recapitulated by BAG‑1 isoform loss, indicating possible polypharmacology or incomplete target engagement; nevertheless, BAG‑1 remains a tractable but challenging target with potentially limited on‑target toxicity inferred from mouse genetics. Molecular Cancer Therapeutics, 2024‑02; URL: https://doi.org/10.1158/1535-7163.mct-23-0354. (neeb2024thio2inhibitskey pages 1-2)
- Prognostic and translational genomics (2024)
  - Liposarcoma (LPS): BAG1 behaves as a protective factor. In dedifferentiated LPS, low BAG1 associates with worse OS (p = 0.0041) and DSS (p = 0.0111); higher BAG1 correlates with better DRFS (p = 0.0095). A 2‑gene BAG1/BAG2 risk model achieved time‑dependent ROC AUCs of ~0.725 (1‑yr), 0.732 (3‑yr), 0.723 (5‑yr) across validation cohorts (TCGA and GSE30929). Sci Rep, 2024‑10; URL: https://doi.org/10.1038/s41598-024-67659-6. (lian2024decipheringtheprognostic pages 3-5, lian2024decipheringtheprognostic pages 12-13)

3) Current applications and real‑world implementations
- Biomarker and prognostic context
  - Breast cancer: BAG1 is incorporated in multigene assays (e.g., Oncotype DX, PAM50) and, meta‑analytically, higher BAG‑1 mRNA and nuclear protein generally correlate with improved outcomes (see Section 5 for statistics). While this is historical, it informs current pathology and risk stratification paradigms. Br J Cancer, 2017‑05‑30; URL: https://doi.org/10.1038/bjc.2017.130. (papadakis2017bag1asa pages 1-2, papadakis2017bag1asa pages 7-8)
  - Liposarcoma: 2024 analyses suggest potential utility of BAG1 (with BAG2) in patient risk stratification and possibly immunologic phenotype interpretation. (lian2024decipheringtheprognostic pages 3-5, lian2024decipheringtheprognostic pages 12-13)
- Therapeutic exploration
  - Anti‑androgen resistance in CRPC: Tool compounds (e.g., Thio‑2) targeting the BAG domain are being explored to diminish AR signaling; translational studies emphasize optimization due to mechanism ambiguity. (neeb2024thio2inhibitskey pages 1-2)
- Proteostasis engineering
  - Mechanistic insights into Hsp70–BAG1–proteasome coupling may guide design of chaperone‑to‑proteasome shuttles or NEF‑modulating strategies to influence degradation of challenging substrates. (maestrolopez2025structuresofthe pages 4-7, maestrolopez2025structuresofthe pages 1-4)

4) Expert opinions and analysis from authoritative sources
- Family‑wide and mechanistic syntheses emphasize that BAG‑1 is an Hsp70/Hsc70 NEF with a UBL that engages the proteasome, supporting a model in which BAG‑1 promotes UPS‑directed proteostasis and interfaces with apoptotic and receptor signaling networks (BCL2, RAF1, steroid receptors). These reviews also position BAG‑1 in a systems context with BAG3, highlighting triage between UPS and autophagy pathways. (lin2025onebagdoesntc pages 11-12, lin2025onebagdoesnt pages 3-4)
- In prostate cancer biology, experts propose the BAG domain as druggable yet challenging; functional genomics and pharmacology suggest on‑target therapeutic windows may be feasible, though current tool molecules need improved specificity/validation. (neeb2024thio2inhibitskey pages 1-2)
- Structural preprint authors argue that BAG‑1 can reconfigure proteasome ATPase states to enable ubiquitin‑independent degradation, a potentially broader paradigm for chaperone‑to‑proteasome delivery beyond classical ubiquitination. While compelling, peer‑review will be important to consolidate this mechanism. (maestrolopez2025structuresofthe pages 4-7, maestrolopez2025structuresofthe pages 1-4)

5) Relevant statistics and data from recent studies
- Breast cancer meta‑analysis (historical benchmark informing current practice)
  - Pooled breast cancer‑specific survival: HR 0.55 (95% CI 0.36–0.85) favoring high BAG1 (mRNA/protein). Multiple cohorts show consistent directionality (e.g., van de Vijver HR 0.44 [0.28–0.70]; Afentakis nuclear BAG‑1 DDFS pooled HR 0.70 [0.59–0.84]). Br J Cancer 2017; URL: https://doi.org/10.1038/bjc.2017.130. (papadakis2017bag1asa pages 6-7, papadakis2017bag1asa pages 7-8, papadakis2017bag1asa pages 8-9)
- Liposarcoma (2024)
  - Directionality: High BAG1 associated with improved OS (p = 0.0041), DSS (p = 0.0111), and DRFS (p = 0.0095) in DDLPS; 2‑gene BAG1/BAG2 risk model AUCs ≈ 0.725 (1‑yr), 0.732 (3‑yr), 0.723 (5‑yr) across cohorts (TCGA, GSE30929). URL: https://doi.org/10.1038/s41598-024-67659-6. (lian2024decipheringtheprognostic pages 3-5, lian2024decipheringtheprognostic pages 12-13)
- Quantitative biophysics (2025 preprint; mechanistic)
  - Affinity estimates: BAG1–Hsp70NBD KD ≈ 50 nM; BAG1–Rpn1 KD ≈ 500 nM; UBL mapped to Rpn1 T2 site by cryo‑EM; proteasome ATPase ring/central channel remodeled upon BAG1 binding. URL: https://doi.org/10.1101/2025.01.22.633148. (maestrolopez2025structuresofthe pages 4-7)

Functional annotation and mechanistic narrative
- Primary function and substrate specificity
  - BAG‑1 is not an enzyme or transporter; it is a co‑chaperone and NEF that regulates Hsp70/Hsc70 ATPase cycling. Through the BAG domain, BAG‑1 binds the Hsp70 NBD to accelerate ADP release; via its UBL, it couples Hsp70‑bound client proteins to the proteasome, biasing processing toward degradation. Substrate “specificity” is therefore indirect and derives from Hsp70 client selection and BAG1‑mediated routing. (maestrolopez2025structuresofthe pages 1-4, maestrolopez2025structuresofthe pages 4-7)
- Signaling and pathway roles
  - Proteostasis triage: BAG‑1 promotes UPS degradation (Hsp70→Rpn1 coupling), whereas BAG3 promotes autophagic routes; cellular fate decisions for misfolded or aggregation‑prone clients depend on the BAG1:BAG3 balance and upstream stress cues. (lin2025onebagdoesnt pages 3-4, lin2025onebagdoesntc pages 11-12)
  - Apoptosis and stress signaling: BAG‑1 binds BCL2 and interacts with RAF1, integrating proteostasis with survival signaling. BAG‑1L nuclear functions modulate steroid receptor transcription (ER/AR), linking chaperone control to hormone‑dependent gene expression. (lin2025onebagdoesntc pages 11-12)
- Subcellular localization and regulatory signals
  - Isoform‑dependent localization: BAG‑1L harbors an N‑terminal NLS and is predominantly nuclear, facilitating receptor modulation; BAG‑1M and BAG‑1S are largely cytosolic and interface with Hsp70/UPS machinery. All but the shortest isoform harbor UBL regions contributing to proteasome engagement. (lin2025onebagdoesnt pages 3-4, neeb2024thio2inhibitskey pages 1-2)

Verification against UniProt fields
- Gene symbol and species: BAG1, Homo sapiens – matched. (lin2025onebagdoesntc pages 11-12)
- Domains: BAG domain (NEF) and UBL region – matched with literature and structural data. (maestrolopez2025structuresofthe pages 4-7, maestrolopez2025structuresofthe pages 1-4)
- Family context: Part of the BAG family (BAG1–BAG6), with conserved BAG domains across members. (lin2025onebagdoesntc pages 11-12)

Embedded summary table
| Feature | Evidence summary | Key details | Source |
|---|---|---:|---|
| Identity / domain architecture | C-terminal BAG domain acts as Hsp70/Hsc70 nucleotide-exchange factor (NEF); N-terminal ubiquitin-like (UBL) domain binds proteasomal Rpn1 to couple Hsp70 clients to the 26S proteasome. | Reported KD ~50 nM (Hsp70NBD) vs ~500 nM (Rpn1); UBL occupies Rpn1 T2 site and Bag1 binding remodels RP conformation enabling ubiquitin-independent proteasomal degradation (cryo-EM, XL-MS). | (maestrolopez2025structuresofthe pages 4-7) Maestro-López et al., bioRxiv 2025: https://doi.org/10.1101/2025.01.22.633148 |
| Isoforms (BAG-1S/M/L) and localization | Multiple isoforms generated by alternative translation initiation; BAG-1L contains an N-terminal NLS and is nuclear, BAG-1M/S are predominantly cytosolic. | Sizes ~50 kDa (BAG-1L/p50), ~46 kDa (BAG-1M/p46), ~36 kDa (BAG-1S/p36); BAG-1L modulates steroid receptor (ER/AR) transcriptional activity. | (neeb2024thio2inhibitskey pages 1-2, lin2025onebagdoesnt pages 3-4) Neeb et al., Mol Cancer Ther 2024: https://doi.org/10.1158/1535-7163.mct-23-0354 |
| Core partners | Direct NEF interaction with Hsp70/Hsc70; reported binding partners include BCL2, RAF1 and steroid receptors (ER/AR). | BAG domain required for Hsp70 binding; interactions implicated in apoptosis inhibition and receptor transactivation/regulation. | (lin2025onebagdoesnt pages 3-4, neeb2024thio2inhibitskey pages 1-2) (lin review 2025; Neeb et al. 2024) |
| Proteostasis roles / pathway placement | BAG1 biases client fate toward proteasomal (UPS) degradation via UBL–Rpn1 coupling; BAG3 shifts fate toward autophagy/aggrephagy—BAG1:BAG3 balance influences triage (UPS vs autophagy). | UBL-mediated recruitment of Hsp70-bound clients to Rpn1 supports ubiquitin-independent routing; BAG3 promotes CASA/autophagic clearance. | (lin2025onebagdoesnt pages 3-4, maestrolopez2025structuresofthe pages 4-7) lin 2025, Maestro-López 2025 preprint |
| 2023–2025 structural highlight | Cryo-EM + XL‑MS reveal ternary Hsp70–Bag1–Rpn1 complex and Bag1UBL occupancy of Rpn1 T2 site; Bag1 binding remodels RP/ATPase conformations. | Structural model supports direct coupling of chaperone-bound clients to proteasome and an ATPase‑remodeling mechanism enabling ubiquitin-independent degradation. | (maestrolopez2025structuresofthe pages 4-7) Maestro-López et al., bioRxiv 2025: https://doi.org/10.1101/2025.01.22.633148 |
| 2024 small-molecule highlight (Thio-2) | Thio-2 and related compounds inhibit BAG-1L–AR transactivation and reduce castration‑resistant prostate cancer (CRPC) model growth; phenotype not fully phenocopied by BAG1 KO. | Demonstrates pharmacologic targeting of BAG domain affects AR signaling and tumor growth, but mechanism may be partially BAG1‑independent in reported assays. | (neeb2024thio2inhibitskey pages 1-2) Neeb et al., Mol Cancer Ther 2024: https://doi.org/10.1158/1535-7163.mct-23-0354 |
| 2024 prognostic data (liposarcoma) | High BAG1 expression associates with improved OS/DSS and better DRFS in dedifferentiated/well-differentiated liposarcoma; BAG1+BAG2− signature shows prognostic value. | Significant p-values for OS/DSS/DRFS; 2-gene risk model time-dependent ROC AUCs ≈ 0.725–0.732 (1–5 yr). Cohorts: TCGA and GSE30929. | (lian2024decipheringtheprognostic pages 3-5, lian2024decipheringtheprognostic pages 12-13) Lian et al., Sci Rep 2024: https://doi.org/10.1038/s41598-024-67659-6 |
| Historical clinical context (breast cancer meta-analysis) | Systematic review/meta-analysis in early breast cancer: higher BAG1 (mRNA and nuclear protein) generally linked to improved outcomes. | Pooled BC-specific survival HR 0.55 (95% CI 0.36–0.85; n≈2422); nuclear BAG-1 DDFS pooled HR 0.70 (95% CI 0.59–0.84). | (papadakis2017bag1asa pages 5-6, papadakis2017bag1asa pages 7-8) Papadakis et al., Br J Cancer 2017: https://doi.org/10.1038/bjc.2017.130 |


*Table: Compact summary table of human BAG1 (UniProt Q99933) features, experimental evidence, functional details and key 2023–2025 developments with primary source pointers.*

References (with URLs and dates when available)
- Maestro‑López M et al. Structures of the 26S proteasome in complex with the Hsp70 cochaperone Bag1 reveal a novel mechanism of ubiquitin‑independent proteasomal degradation. bioRxiv. Posted 2025‑01‑22. URL: https://doi.org/10.1101/2025.01.22.633148 (preprint). (maestrolopez2025structuresofthe pages 4-7, maestrolopez2025structuresofthe pages 1-4)
- Neeb A et al. Thio‑2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration‑resistant Prostate Cancer. Mol Cancer Ther. 2024‑02;23:791‑808. URL: https://doi.org/10.1158/1535-7163.mct-23-0354. (neeb2024thio2inhibitskey pages 1-2)
- Lian Y et al. Deciphering the prognostic and therapeutic significance of BAG1 and BAG2 for predicting distinct survival outcome and effects on liposarcoma. Sci Rep. 2024‑10. URL: https://doi.org/10.1038/s41598-024-67659-6. (lian2024decipheringtheprognostic pages 3-5, lian2024decipheringtheprognostic pages 12-13)
- Papadakis E et al. BAG‑1 as a biomarker in early breast cancer prognosis: a systematic review with meta‑analyses. Br J Cancer. 2017‑05‑30;116:1585‑1594. URL: https://doi.org/10.1038/bjc.2017.130. (papadakis2017bag1asa pages 5-6, papadakis2017bag1asa pages 6-7, papadakis2017bag1asa pages 7-8, papadakis2017bag1asa pages 8-9, papadakis2017bag1asa pages 1-2)
- Lin H et al. One BAG doesn’t fit all: the differences and similarities of BAG family members in mediating CNS homeostasis. 2025 (review). (lin2025onebagdoesnt pages 11-12, lin2025onebagdoesnta pages 11-12, lin2025onebagdoesntb pages 11-12, lin2025onebagdoesnt pages 3-4, lin2025onebagdoesntc pages 11-12)

Limitations and open questions
- The proteasome structural mechanism for BAG‑1‑mediated ubiquitin‑independent degradation is currently supported by a 2025 preprint; peer‑review will be important to validate conformational assignments and physiological scope. (maestrolopez2025structuresofthe pages 4-7, maestrolopez2025structuresofthe pages 1-4)
- Thio‑2’s exact target engagement on the BAG domain versus off‑targets remains to be resolved; medicinal chemistry efforts are warranted to clarify on‑target pharmacology. (neeb2024thio2inhibitskey pages 1-2)

References

1. (lin2025onebagdoesntc pages 11-12): H Lin, S Ramanan, S Kaplan, and DH King. One bag doesn't fit all: the differences and similarities of bag family members in mediating cns homeostasis. Unknown journal, 2025.

2. (maestrolopez2025structuresofthe pages 1-4): Moisés Maestro-López, Tat Cheung Cheng, Jimena Muntaner, Margarita Menéndez, Melissa Alonso, Andreas Schweitzer, Jorge Cuéllar, José María Valpuesta, and Eri Sakata. Structures of the 26s proteasome in complex with the hsp70 cochaperone bag1 reveal a novel mechanism of ubiquitin-independent proteasomal degradation. bioRxiv, Jan 2025. URL: https://doi.org/10.1101/2025.01.22.633148, doi:10.1101/2025.01.22.633148. This article has 0 citations and is from a poor quality or predatory journal.

3. (maestrolopez2025structuresofthe pages 4-7): Moisés Maestro-López, Tat Cheung Cheng, Jimena Muntaner, Margarita Menéndez, Melissa Alonso, Andreas Schweitzer, Jorge Cuéllar, José María Valpuesta, and Eri Sakata. Structures of the 26s proteasome in complex with the hsp70 cochaperone bag1 reveal a novel mechanism of ubiquitin-independent proteasomal degradation. bioRxiv, Jan 2025. URL: https://doi.org/10.1101/2025.01.22.633148, doi:10.1101/2025.01.22.633148. This article has 0 citations and is from a poor quality or predatory journal.

4. (neeb2024thio2inhibitskey pages 1-2): Antje Neeb, Ines Figueiredo, Denisa Bogdan, Laura Cato, Jutta Stober, Juan M. Jiménez-Vacas, Victor Gourain, Irene I. Lee, Rebecca Seeger, Claudia Muhle-Goll, Bora Gurel, Jonathan Welti, Daniel Nava Rodrigues, Jan Rekowski, Xintao Qiu, Yija Jiang, Patrizio Di Micco, Borja Mateos, Stasė Bielskutė, Ruth Riisnaes, Ana Ferreira, Susana Miranda, Mateus Crespo, Lorenzo Buroni, Jian Ning, Suzanne Carreira, Stefan Bräse, Nicole Jung, Simone Gräßle, Amanda Swain, Xavier Salvatella, Stephen R. Plymate, Bissan Al-Lazikani, Henry W. Long, Wei Yuan, Myles Brown, Andrew C. B. Cato, Johann S. De Bono, and Adam Sharp. Thio-2 inhibits key signaling pathways required for the development and progression of castration-resistant prostate cancer. Molecular Cancer Therapeutics, 23:791-808, Feb 2024. URL: https://doi.org/10.1158/1535-7163.mct-23-0354, doi:10.1158/1535-7163.mct-23-0354. This article has 3 citations and is from a peer-reviewed journal.

5. (lian2024decipheringtheprognostic pages 3-5): Yingying Lian, Jiahao Chen, Jiayang Han, Binbin Zhao, Jialin Wu, Xinyu Li, Man Yue, Mengwen Hou, Tinggai Wu, Ting Ye, Xu Han, Tiantian Sun, Mengjie Tu, Kaifeng Zhang, Guangchao Liu, and Yang An. Deciphering the prognostic and therapeutic significance of bag1 and bag2 for predicting distinct survival outcome and effects on liposarcoma. Scientific Reports, Oct 2024. URL: https://doi.org/10.1038/s41598-024-67659-6, doi:10.1038/s41598-024-67659-6. This article has 0 citations and is from a peer-reviewed journal.

6. (lian2024decipheringtheprognostic pages 12-13): Yingying Lian, Jiahao Chen, Jiayang Han, Binbin Zhao, Jialin Wu, Xinyu Li, Man Yue, Mengwen Hou, Tinggai Wu, Ting Ye, Xu Han, Tiantian Sun, Mengjie Tu, Kaifeng Zhang, Guangchao Liu, and Yang An. Deciphering the prognostic and therapeutic significance of bag1 and bag2 for predicting distinct survival outcome and effects on liposarcoma. Scientific Reports, Oct 2024. URL: https://doi.org/10.1038/s41598-024-67659-6, doi:10.1038/s41598-024-67659-6. This article has 0 citations and is from a peer-reviewed journal.

7. (papadakis2017bag1asa pages 7-8): E. Papadakis, T. Reeves, Natalia Robson, T. Maishman, G. Packham, and R. Cutress. Bag-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses. British Journal of Cancer, 116:1585-1594, May 2017. URL: https://doi.org/10.1038/bjc.2017.130, doi:10.1038/bjc.2017.130. This article has 32 citations and is from a domain leading peer-reviewed journal.

8. (lin2025onebagdoesnt pages 3-4): H Lin, S Ramanan, S Kaplan, and DH King. One bag doesn't fit all: the differences and similarities of bag family members in mediating cns homeostasis. Unknown journal, 2025.

9. (papadakis2017bag1asa pages 1-2): E. Papadakis, T. Reeves, Natalia Robson, T. Maishman, G. Packham, and R. Cutress. Bag-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses. British Journal of Cancer, 116:1585-1594, May 2017. URL: https://doi.org/10.1038/bjc.2017.130, doi:10.1038/bjc.2017.130. This article has 32 citations and is from a domain leading peer-reviewed journal.

10. (papadakis2017bag1asa pages 6-7): E. Papadakis, T. Reeves, Natalia Robson, T. Maishman, G. Packham, and R. Cutress. Bag-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses. British Journal of Cancer, 116:1585-1594, May 2017. URL: https://doi.org/10.1038/bjc.2017.130, doi:10.1038/bjc.2017.130. This article has 32 citations and is from a domain leading peer-reviewed journal.

11. (papadakis2017bag1asa pages 8-9): E. Papadakis, T. Reeves, Natalia Robson, T. Maishman, G. Packham, and R. Cutress. Bag-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses. British Journal of Cancer, 116:1585-1594, May 2017. URL: https://doi.org/10.1038/bjc.2017.130, doi:10.1038/bjc.2017.130. This article has 32 citations and is from a domain leading peer-reviewed journal.

12. (papadakis2017bag1asa pages 5-6): E. Papadakis, T. Reeves, Natalia Robson, T. Maishman, G. Packham, and R. Cutress. Bag-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses. British Journal of Cancer, 116:1585-1594, May 2017. URL: https://doi.org/10.1038/bjc.2017.130, doi:10.1038/bjc.2017.130. This article has 32 citations and is from a domain leading peer-reviewed journal.

13. (lin2025onebagdoesnt pages 11-12): H Lin, S Ramanan, S Kaplan, and DH King. One bag doesn't fit all: the differences and similarities of bag family members in mediating cns homeostasis. Unknown journal, 2025.

14. (lin2025onebagdoesnta pages 11-12): H Lin, S Ramanan, S Kaplan, and DH King. One bag doesn't fit all: the differences and similarities of bag family members in mediating cns homeostasis. Unknown journal, 2025.

15. (lin2025onebagdoesntb pages 11-12): H Lin, S Ramanan, S Kaplan, and DH King. One bag doesn't fit all: the differences and similarities of bag family members in mediating cns homeostasis. Unknown journal, 2025.

## Citations

1. maestrolopez2025structuresofthe pages 1-4
2. maestrolopez2025structuresofthe pages 4-7
3. lin2025onebagdoesntc pages 11-12
4. lian2024decipheringtheprognostic pages 3-5
5. lian2024decipheringtheprognostic pages 12-13
6. lin2025onebagdoesnt pages 3-4
7. lin2025onebagdoesnt pages 11-12
8. lin2025onebagdoesnta pages 11-12
9. lin2025onebagdoesntb pages 11-12
10. 0.28–0.70
11. 0.59–0.84
12. https://doi.org/10.1101/2025.01.22.633148
13. https://doi.org/10.1158/1535-7163.mct-23-0354.
14. https://doi.org/10.1038/s41598-024-67659-6.
15. https://doi.org/10.1038/bjc.2017.130.
16. https://doi.org/10.1101/2025.01.22.633148.
17. https://doi.org/10.1158/1535-7163.mct-23-0354
18. https://doi.org/10.1038/s41598-024-67659-6
19. https://doi.org/10.1038/bjc.2017.130
20. https://doi.org/10.1101/2025.01.22.633148,
21. https://doi.org/10.1158/1535-7163.mct-23-0354,
22. https://doi.org/10.1038/s41598-024-67659-6,
23. https://doi.org/10.1038/bjc.2017.130,